The International Association for the Study of Lung Cancer (IASLC) shared a post on X:
“Zosia Piotrowska and Joshua Sabari sparred on whether novel TKIs should take the gold as first-line treatment for EGFR or HER2 exon 20 mutations.
Read the highlights from TTLC 2026 in ILCN.”
Other articles about IASLC on OncoDaily.